MiNK Therapeutics (INKT) CEO Buell Jennifer Sells $73K of Stock

Jennifer Buell, the Chief Executive Officer of MiNK Therapeutics, Inc. (NasdaqCM: INKT), sold 6,938 shares on October 12, 2026. The sale was valued at approximately $73,265, with the shares priced at $10.56 each. This transaction was not part of a planned trading strategy.

Inside Buell's Trade

Buell's recent sale adds to her existing holdings but does not change her position significantly. After this transaction, it remains to be seen how her stake will evolve given the current market conditions.

Other Institutional Activity in MiNK Therapeutics

Vanguard Capital Management LLC holds 68,660 shares of MiNK Therapeutics, valued at approximately $646,090, having increased its position by 9,296 shares. DnB Asset Management AS also boosted its stake by 27,571 shares, ending with 55,142 shares worth about $518,886. Citadel Advisors LLC increased its holdings by 7,720 shares, bringing its total to 15,440 shares valued at around $145,290. Geode Capital Management, LLC reduced its stake by 1,773 shares, now holding 15,573 shares worth approximately $146,541.

MiNK Therapeutics, Inc. Stock Down 3.1%

As of October 16, 2026, MiNK Therapeutics was recently trading around $9.63, which is below its 50-day moving average of approximately $11.56 and its 200-day average of about $11.38. The stock is also 43.1% below its 52-week high of $16.93, indicating a challenging period for the company.

Recent Earnings

MiNK Therapeutics reported no earnings in the last twelve months, with an EPS of -$2.39. The next earnings date is set for November 12, 2026, which will provide further insights into the company's financial health.

Insider Buying and Selling at MiNK Therapeutics, Inc.

In addition to Buell's sale, Director Barbara Ryan has sold shares on multiple occasions earlier this year. On March 2, 2026, she sold 500 shares, followed by another sale of 1,500 shares on March 10, and an additional 1,500 shares on June 4, totaling 3,500 shares sold in 2026.

About MiNK Therapeutics

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New York, NY. It focuses on developing innovative therapies using invariant natural killer T (iNKT) cells to treat cancer and other immune-related diseases. This recent insider activity reflects the current sentiment and strategic decisions within the company.

Bottom Line

Investors will be watching for MiNK Therapeutics' next earnings report on November 12, 2026, and further insider transactions that may indicate management's outlook. Buell's recent sale, while significant, is part of a broader pattern of insider activity at the company.